Hospitals & Healthcare Pressreleases

This section covers the managerial aspects in the Healthcare industry.

Ascletis Initiates Phase II Clinical Trial of Its Interferon-Free HCV Regimen in Taiwan

Monday, August 31, 2015
PR Newswire

SHAOXING China Aug 31 2015 PRNewswire Ascletis today announced it received the approval from the Taiwan Food and Drug Administration TFDA to start phase II clinical trial for its alloral interferon IFNfree regimen to treat chronic hepatitis C CHC The regimen contains Ascletis two directacting..

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 \'apabetalone\' a Selective BET Inhibitor

Monday, August 31, 2015
PR Newswire

I am pleased to share this important new data on RVX208 apabetalone as we embark on our Phase 3 clinical trial BETonMACE Dr Norman Wong LONDON UK and CALGARY Aug 31 2015 CNW Resverlogix Corp Resverlogix or the Company TSXRVX is pleased to announce that Dr Norman Wong chief scientific officer ..

AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients

Monday, August 31, 2015
PR Newswire

ALBANY NY Aug 31 2015 PRNewswire AMRI NASDAQ AMRI and Saneca Pharmaceuticals as today announced a strategic collaboration focused on the development manufacture and marketing of a portfolio of opiumderived active pharmaceutical ingredients APIs The collaboration combines Sanecas strength in extrac..

Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Monday, August 31, 2015
PR Newswire

PRINCETON NJ Aug 31 2015 PRNewswire Soligenix Inc OTCQB SNGX Soligenix or the Company a latestage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation oncology and biodefense announced today it has completed enrollment of the additional subje..

BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ

Monday, August 31, 2015
PR Newswire

TEL AVIV Israel August 31 2015 PRNewswire BioLight Life Sciences Investments Ltd TASE BOLT OTCQX BLGTY BioLight or the Company a firm that invests in manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics today announced that its cancer diagnostics subsidiary M..

RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109

Monday, August 31, 2015
PR Newswire

MARLBOROUGH Mass Aug 31 2015 PRNewswire RXi Pharmaceuticals Corporation NASDAQ RXII a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced that the 30day review period following the filing of the Co..

Novogen Announces The Outcome Of A Comprehensive Science Review

Monday, August 31, 2015
PR Newswire

SYDNEY Aug 31 2015 PRNewswire USAustralian drug discovery company Novogen Limited ASX NRT NASDAQ NVGN today confirmed its comprehensive scientific review has identified high value opportunities for its groundbreaking technology platforms in areas of unmet patient need Novogen is moving as quickly ..

Qualcomm Life Announces New Connected Health Collaborations at Connect 2015

Monday, August 31, 2015
PR Newswire

SAN DIEGO Aug 31 2015 PRNewswire Qualcomm Incorporated NASDAQ QCOM today announced that its subsidiary Qualcomm Life Inc is collaborating with Davita Healthcare Partners and P2Link to develop chronic care management solutions powered by Qualcomm Lifes 2net Device Connectivity Platform and HealthyC..

Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant

Monday, August 31, 2015
PR Newswire

WOODCLIFF LAKE NJ and STAMFORD Conn Aug 31 2015 PRNewswire Eisai Inc the US pharmaceutical subsidiary of Eisai Co Ltd and Purdue Pharma LP announced today that they have entered into a worldwide collaboration agreement for the development and commercialization of Eisais clinical candidate lemborex..

Global sales and marketing firm ZS opens Singapore office

Monday, August 31, 2015
PR Newswire

EVANSTON Ill Aug 31 2015 PRNewswire In a move to expand its presence in the AsiaPacific region global sales and marketing firm ZS recently opened an office in Singapore The new office is ZSs fifth location in Asia and 22nd worldwide Dedicated to helping companies around the world and across multi..

LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution

Monday, August 31, 2015
PR Newswire

CAESAREA Israel Aug 31 2015 PRNewswire LabStyle Innovations Corp OTCQB DRIO developer of the Dario Diabetes Management Solution today announced it recently closed a round of funding totaling approximately 25 million Funds will be used to support the global rollout and initial US commercial launch..

Duchesnay USA Publishes Corrective Messaging through Kim Kardashian\'s Social Media Accounts in Response to FDA\'s Request

Monday, August 31, 2015
PR Newswire

ROSEMONT Pa Aug 31 2015 PRNewswire Duchesnay USA announced that it has taken corrective action to address the US Food and Drug AdministrationsOffice of Prescription Drug PromotionOPDP Warning Letter regarding omission of risk information and important limitations of use for Diclegis doxylamine suc..

More than 100 Lives Reported Saved Since Launch of the \"kaleo Cares\" EVZIO® (naloxone HCl injection) Donation Program

Monday, August 31, 2015
PR Newswire

RICHMOND Va Aug 31 2015 PRNewswire Kalo a privatelyheld pharmaceutical company today announced that EVZIO naloxone HCl injection AutoInjectorsdonated through their charitable donation program kalo Careshave been administered to help save more than 100 lives since inception of the charitable progra..

FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925

Monday, August 31, 2015
PR Newswire

SOUTH SAN FRANCISCO Calif Aug 31 2015 PRNewswire FLX Bio Inc a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies announced today that it has appointed Brian Wong MD PhD as Chief Executive Officer and William Ho MD PhD as Chief Medical Officer Drs W..

Allergan Successfully Completes Naurex Acquisition

Monday, August 31, 2015
PR Newswire

DUBLIN Aug 31 2015 PRNewswire Allergan plc NYSE AGN a leading global pharmaceutical company today announced that it has successfully completed the acquisition of Naurex Inc a clinicalstage biopharmaceutical company d..

Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September

Monday, August 31, 2015
PR Newswire

NEW YORK Aug 31 2015 PRNewswire Dipexium Pharmaceuticals Inc NASDAQ DPRX a latestage pharmaceutical company focused on the development and commercialization of Locilex pexiganan cream 08 a novel broad spectrum topical antibiotic peptide today announced plans to participate in four investor confere..

Trimb Acquires YouMedical To Build North European OTC Platform

Monday, August 31, 2015
PR Newswire

STOCKHOLM Aug 31 2015 PRNewswire Trimb Healthcare AB Trimb today announced that it has signed an agreement to acquire YouMedical Group BV YouMedical a Dutch OTC company with operations in key European markets YouMedical has total annual sales of approximately EUR 16 million with solid growth and ..

Pazoo Signs Deal With New Consulting Company, Luchesi & Brand LLC

Monday, August 31, 2015
PR Newswire

WHIPPANY NJ Aug 31 2015 PRNewswire Pazoo Inc OTC PinksPZOO German WKN A1J3DK is pleased to announce it has signed a contract with Luchesi Brand LLC Luchesi Brand will help and assist Pazoo with meeting the capital needs for the company help secure additional grower contracts in all three states ..

MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections

Monday, August 31, 2015
PR Newswire

HAYWARD Calif and SHANGHAI Aug 31 2015 PRNewswire MicuRx Pharmaceuticals Inc a privatelyheld biopharmaceutical company developing nextgeneration antibiotics today announced positive topline results from the first Phase 2 clinical study for its lead drug candidate MRXI MRXI is an oral oxazolidinone..

Channel Medsystems Secures $22 Million Series C Financing Led by Third Point Ventures

Monday, August 31, 2015
PR Newswire

Company Prepares to Initiate a Pivotal Study for its Novel OfficeBased Therapy for Women with Heavy Menstrual Bleeding SAN FRANCISCO Aug 31 2015 PRNewswire Channel Medsystems today announced a 22 million Series C financing led by Third Point VenturesAdditional participants in the round include..

TOP